- Conditions
- CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
- Interventions
- Pencil Beam Scanning Proton Therapy
- Radiation
- Lead sponsor
- The New York Proton Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 239
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Myelodysplastic Syndrome, Lymphoma
- Interventions
- CliniMACS Fractionation system (Arm A), CliniMACS Fractionation system (Arm B), Haploidentical donor CD34+ cells
- Device · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
- Interventions
- mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT, Gemcitabine
- Drug · Biological · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Crenolanib, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Sacramento, California • Gainesville, Florida • Chicago, Illinois + 4 more
- Conditions
- Melanoma
- Interventions
- Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
- Drug · Biological · Other
- Lead sponsor
- Diwakar Davar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, in Relapse
- Interventions
- pembrolizumab,
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Chapel Hill, North Carolina
- Conditions
- Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System
- Drug · Device
- Lead sponsor
- Everett Meyer
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Large B-Cell Diffuse Lymphoma
- Interventions
- Oral azacitidine, R-ICE
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 22 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Sirolimus, Mitoxantrone, Etoposide, Cytarabine
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Interventions
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
- Drug · Biological · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
- Conditions
- Perioperative Optimization
- Interventions
- Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1
- Drug
- Lead sponsor
- Jennifer Holder-Murray
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast- Enhanced (DCE) MRI
- Diagnostic Test
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- CPX-351
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stroke, Acute, Intracranial Hemorrhages
- Interventions
- Y-2(Edaravone And Borneol) Sublingual Tablet
- Drug
- Lead sponsor
- Yantai YenePharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Leukemia, Lymphocytic, Acute
- Interventions
- Methotrexate, Vincristine, PEG-l-asparaginase, Dexamethasone, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
- Interventions
- paclitaxel, ifosfamide, cisplatin, pegylated G-CSF, G-CSF, carboplatin, etoposide phosphate, stem cell reinfusion
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 14 Years and older · Male only
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, ifosfamide, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
- Conditions
- Secondary Acute Myeloid Leukemia
- Interventions
- Venetoclax, FLAG or CLAG Protocol
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2014
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Filgrastim, Genetically Engineered Lymphocyte Therapy, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Plerixafor, Rituximab
- Procedure · Biological · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT)
- Drug · Radiation
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more